**Sir**,

In their publication 'Mathematical models of targeted cancer therapy\' [Abbott and Michor (2006)](#bib1){ref-type="other"} emphasise the role of theoretical modelling for the understanding of cancer initiation, progression and treatment. Herein, they draw a number of general conclusions from a model of BCR-ABL1-positive chronic myeloid leukaemia (CML) under imatinib treatment that has recently been published by [Michor *et al* (2005)](#bib2){ref-type="other"}. This model relies on the existence of four subsequent compartments, through which haematopoietic cell differentiation proceeds. Chronic myeloid leukaemia development is initiated by the mutation of a single stem cell, and the expansion of the malignant (i.e. BCR-ABL1-positive) clone is assumed to be completely independent of the normal cells. Imatinib treatment, which is known to specifically affect BCR-ABL1-positive cells, is assumed to act on progenitor and differentiated cells only. In contrast, malignant stem cells are not affected and continue to expand exponentially. [Abbott and Michor (2006)](#bib1){ref-type="other"} show that these assumptions are consistent with clinical data on BCR-ABL1 transcript levels during the first year of imatinib treatment as well as after treatment cessation.

Recent data on the long-term development of CML under imatinib monotherapy show a continuing decrease of BCR-ABL1 transcript levels even after the first year of treatment ([Roeder *et al*, 2006](#bib3){ref-type="other"}) ([Figure 1A](#fig1){ref-type="fig"}). This long-term behaviour cannot be explained within the model of CML dynamics discussed by [Abbott and Michor (2006)](#bib1){ref-type="other"}. Owing to the contribution of CML cells from the exponentially growing malignant stem cell compartment, this model inevitably predicts a relapse of BCR-ABL1 transcript levels after about 1.5 years, even under continuing imatinib treatment and without the occurrence of resistance mutations ([Figure 1B](#fig1){ref-type="fig"}).

Within the aforementioned publication ([Roeder *et al*, 2006](#bib3){ref-type="other"}), our group proposed an alternative explanation of the imatinib effect, which is consistent with the observed short- and long-term BCR-ABL1 levels ([Figure 1C](#fig1){ref-type="fig"}) as well as with the relapse dynamics after treatment cessation. In contrast to the model described by Abbott and Michor, we predict a selective imatinib effect on proliferating BCR-ABL1-positive cells, including stem cells, whenever they are activated into cell cycle.

In the light of the clinical long-term data, complemented by our alternative explanation of the imatinib effect, the statement by Abbott and Michor -- 'the conclusion that leukaemic stem cells cannot be depleted by imatinib can safely be drawn\' -- cannot be uphold. In order to correctly describe the long-term dynamics of BCR-ABL1 transcript levels, certain modifications of the model are unavoidable. Such modifications could include a (possibly reduced) imatinib effect on malignant stem cells or a saturating growth kinetics of the malignant stem cell population.

It should be noted that although our explanation of the imatinib effect is consistent with the clinically observed long-term behaviour, it still remains a hypothesis and might not be without alternative. Particularly in comparison to the hypothesis discussed by [Abbott and Michor (2006)](#bib1){ref-type="other"}, the proposed role of the cell-cycle status of leukaemic stem cells might point to an important aspect of the imatinib effect and possibly other tyrosine kinase inhibitors. It is a particular strength of mathematical models to provide testable predictions and, therefore, to guide experimental and clinical research. However, a definite answer whether any proposed mode of imatinib action is true or not can only be given by data-based validation.

![BCR-ABL1 transcript dynamics for CML under imatinib treatment: (**A**) Datapoints represent median and interquartile range of BCR-ABL1 transcript levels in peripheral blood, determined in two independent study populations: BCR-ABL1/BCR percentages of 68 individuals with imatinib-treated CML over 1 year, previously published by [Michor *et al* (2005)](#bib2){ref-type="other"} (open circles) and BCR-ABL1/ABL1 percentages of 69 individuals with imatinib-treated CML from the German cohort of the IRIS trial over 5.5 years, previously published by [Roeder *et al* (2006)](#bib3){ref-type="other"} (filled circles). (**B**) Long-term simulation results of BCR-ABL1 levels according to the model discussed by [Abbott and Michor (2006)](#bib1){ref-type="other"}. Parameters are taken from the original publication of this model ([Michor *et al*, 2005](#bib2){ref-type="other"}). (**C**) Long-term simulation results of BCR-ABL1 levels according to the model introduced by [Roeder *et al* (2006)](#bib3){ref-type="other"}. Parameters are taken from the given reference.](6603603f1){#fig1}
